More recently, treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) agonists—and most recent with SGLT2 inhibitors in combination with non-steroid mineralocorticoid antagonists—has demonstrated beneficial effects in delaying CKD progression, and reducing cardiovascular events and mortality.29, 30, 31, 32 However, these pharmacological treatments remain underutilised despite their proven benefits. Here, GCG is linked to chronic kidney disease.